Skip to content
sellWeak10b5-1 plan

John Charles Thomas sold $347k of KRYS

EVP, General Counsel at Krystal Biotech, Inc.. 1,000 shares at an average of $347.27, traded Jun 25, 2026, filed Jun 26, 2026.

Warning score
15
Value
$347k
1,000 shares
Holdings after
0
-100% from before
From 52-week low
+167%
low $134.94, close $359.93
From 52-week high
0%
high $359.93, as of Jun 25, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $347k at market
    +15
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

KRYSOct 12, 2026 · close 332.07
Since filing Jun 26, 2026: -10.8%SPY +7.0% · excess -17.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0002114900-26-000009, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 25, 2026MOption exercise
Common Stock10b5-1
+1,000$179.25$179k1,000Jun 26, 2026
Jun 25, 2026SOpen-market sale
Common Stock10b5-1
-1,000$347.27$347k0Jun 26, 2026
Jun 25, 2026MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-1,000$0.00$06,500Jun 26, 2026

Related signals

Other insiders at Krystal Biotech, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$9.0M
25,000 shares
-2%
33Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$9.0M
25,000 shares
-2%
50Moderate
KRYSsell
Krystal Biotech, Inc.
Dino A Rossi
director
$8.2M
25,000 shares
-33%
45Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$7.7M
25,000 shares
-2%
40Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$7.7M
25,000 shares
-2%
42Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
John Charles Thomas
EVP, General Counsel
$194k
642 shares
-100%
45Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$6.6M
25,000 shares
-2%
40Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$6.6M
25,000 shares
-2%
40Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Daniel Janney
director
$3.3M
11,803 shares
-14%
7Weak
KRYSsell 510b5-1
Krystal Biotech, Inc.
Kathryn Romano
Chief Accounting Officer
$201k
750 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

John Charles Thomas sold $347k of KRYS | InsiderTell